Previous 10 | Next 10 |
2023-03-21 11:18:17 ET Wells Fargo said that Zymeworks ( NASDAQ: ZYME ) is a buy citing the biotech's potential royalty streams and milestones from its lead oncology candidate. The firm has a $12 price target (~41% upside based on Monday's close). Derek Archila wrote t...
2023-03-20 10:32:52 ET Zymeworks ( NASDAQ: ZYME ) held steady on Monday despite an announcement over Japanese pharma Daiichi Sankyo's ( OTCPK:DSKYF ) decision to end a six-year exclusive partnership with its subsidiary Zymeworks BC for bispecific antibody products. Und...
2023-03-08 08:36:27 ET Fresh Tracks Therapeutics ( FRTX ) +83% on announcing positive topline results from single and multiple ascending dose parts of phase 1 study of Oral DYRK1A Inhibitor FRTX-02. Kimball International ( KBAL ) +75% HNI to acquire Kimball i...
2023-03-08 08:19:20 ET Zymeworks ( NASDAQ: ZYME ) perks up 11% premarket after announcing financial results for Q4 ended December 31, 2022 on March 7, 2023. Q4 Revenue of $402.5M, consisting of R&D collaborations, significantly higher than estimate of $214.3M. ...
2023-03-07 23:15:04 ET Zymeworks Inc. (ZYME) Q4 2022 Earnings Conference Call March 07, 2023 04:30 PM ET Company Participants Jack Spinks - Head of Investor Relations Chris Astle - Senior Vice President & Chief Financial Officer Kenneth Galbraith - Chair &...
2023-03-07 20:01:51 ET The following slide deck was published by Zymeworks Inc. in conjunction with their 2022 Q4 earnings call. For further details see: Zymeworks Inc. 2022 Q4 - Results - Earnings Call Presentation
2023-03-07 16:17:38 ET Zymeworks press release ( NASDAQ: ZYME ): Q4 GAAP EPS of $4.65 beats by $2.16 . Revenue of $402.49M (+1925.6% Y/Y) beats by $188.16M . For further details see: Zymeworks GAAP EPS of $4.65 beats by $2.16, revenue of $402.49M beats by...
2022 was a year of transformation and change: reported $412.5 million in total revenue for the year ended December 31, 2022; reported net income of $124.3 million ($1.90 per fully diluted share) for 2022 compared to net loss of $211.8 million in 2021; reported $492.2 milli...
2023-03-06 17:35:33 ET Major earnings expected after the bell on Tuesday include: CrowdStrike Holdings ( CRWD ) Stitch Fix ( SFIX ) Cherry Hill Mortgage Investment Corporation ( CHMI ) Yext ( YEXT ) W&T Offshore ( WTI ) For further details...
2023-03-06 17:35:22 ET Zymeworks ( NASDAQ: ZYME ) is scheduled to announce Q4 earnings results on Tuesday, March 7th, after market close. The consensus EPS Estimate is $3.11 (+414.1% Y/Y) and the consensus Revenue Estimate is $214.33M (+978.7% Y/Y). Over the last 2 yea...
News, Short Squeeze, Breakout and More Instantly...
VANCOUVER, British Columbia, July 22, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that the Un...
VANCOUVER, British Columbia, July 11, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that manage...
VANCOUVER, British Columbia, June 17, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that the Un...